Quest Diagnostics Incorporated
Clinical Laboratory Services / Diagnostic Information ServicesFounded 1967- Updated July 2025
Reviewed by Swet Parvadiya
Last reviewed: July 2025
CorpDigest
Quest Diagnostics Incorporated
Company History
Founded 1967 in Secaucus, New Jersey, United States
Last reviewed: 2025-07-15 · By Swet Parvadiya
Quest Diagnostics Incorporated is generating $11.04 billion in annual revenue with 15.9% adjusted operating margins while processing over 220 million diagnostic requisitions annually and maintaining clinical laboratory data on more than 65% of the U.S. population—the most comprehensive health data repository outside government agencies. The company's fiscal 2025 results demonstrated strong execution: revenue grew 11.8%, operating income surged 15.6%, and cash from operations exploded 41.4% to $1.89 billion. The August 2024 acquisition of LifeLabs for CAD $1.35 billion established Quest as the dominant laboratory provider in Canada, while the 2025 Spectra Laboratories acquisition from Fresenius Medical Care expanded renal testing to 200,000+ dialysis patients. Under CEO Jim Davis, Quest is executing a three-pillar strategy—core diagnostic services growth through hospital outreach, advanced diagnostics expansion in Alzheimer's and oncology, and consumer-initiated testing through QuestDirect—that positions the company to benefit from an aging population, chronic disease prevalence, and diagnostic innovation.
Dr. Paul A. Brown was the founder of Metropolitan Pathology Laboratory, Inc. in 1967, the predecessor company to Quest Diagnostics. A practicing pathologist, Brown established the laboratory in Teaneck, New Jersey, to provide clinical pathology and anatomic pathology services to physicians and hospitals in the region. In 1969, the company was renamed MetPath, Inc. Brown led the company's early growth through clinical excellence and physician relationships before Corning Glass Works acquired MetPath in 1982. Brown's founding established the clinical culture and quality focus that would define Quest Diagnostics throughout its evolution from a small regional lab to a global diagnostic enterprise.
Dr. Paul A. Brown founded Metropolitan Pathology Laboratory, Inc. in Teaneck, New Jersey, to provide clinical laboratory services to local physicians and hospitals. The company was renamed MetPath, Inc. in 1969.
Corning Glass Works acquired MetPath and renamed it Corning Clinical Laboratories. This acquisition provided capital and corporate infrastructure for expansion but also meant the laboratory business was a small division within a larger materials science company.
On December 31, 1996, Quest Diagnostics became an independent company through a spin-off from Corning and began trading on the NYSE under ticker DGX. Kenneth W. Freeman was appointed CEO. The spin-off provided strategic flexibility to pursue an acquisition-driven growth strategy.
Quest acquired SmithKline Beecham Clinical Laboratories for approximately $1.3 billion in cash and stock. SBCL had generated $1.6 billion in 1998 revenue and added a national network of laboratories, patient service centers, and a medical sample transport airline. The acquisition doubled Quest's size and established it as the industry leader.
Quest acquired Unilab Corporation for $800 million, significantly expanding its West Coast presence and adding substantial volume in California and surrounding states. The acquisition required divestiture of certain Northern California assets to LabCorp for antitrust clearance.
Quest acquired LabOne, Inc. for $934 million, adding employer drug testing and paramedical testing capabilities that expanded the company's service offerings beyond traditional clinical laboratory testing.
Quest acquired AmeriPath and its subsidiary Specialty Laboratories for approximately $1.23 billion, adding anatomic pathology and cancer diagnostic testing capabilities that complemented Quest's clinical chemistry strengths.
Quest acquired Athena Diagnostics (neurodegenerative disease testing) and Celera Corporation (genomics and sequencing), adding advanced diagnostics capabilities in neurology and genetic testing that would become foundational for future growth initiatives.
Quest acquired Solstas Lab Partners Group for $570 million, expanding its geographic footprint in the Southeastern United States and adding hospital outreach laboratory relationships.
Quest launched QuestDirect, a consumer-initiated testing service that allows patients to order health and wellness lab testing without a physician order in states where permitted. This marked Quest's entry into the direct-to-consumer diagnostic market.
Quest launched COVID-19 testing in March 2020 and by July 2020 had performed more than 9.2 million molecular tests and 2.8 million serology tests. The pandemic created both operational challenges and substantial revenue opportunities for the company.
Quest acquired Blueprint Genetics (Helsinki, Finland) for $108 million, adding genetic testing capabilities for rare diseases and expanding Quest's international genomics expertise.
Jim Davis succeeded Steve Rusckowski as CEO on November 1, 2022, after serving as Executive Vice President of General Diagnostics. Davis brought experience from GE Healthcare, InSightec, and McKinsey & Company. He became Chairman on April 1, 2023.
Quest acquired Haystack Oncology, a minimal residual disease testing company, and the outreach laboratory operations of NewYork-Presbyterian Hospital for $275 million, expanding advanced oncology diagnostics and health system partnerships.
Quest completed the acquisition of LifeLabs from OMERS for approximately CAD $1.35 billion (USD ~$1 billion), adding Canada's leading laboratory diagnostic provider with 6,500+ employees, 8+ million online portal users, and approximately CAD $970 million in annual revenue. LifeLabs continues to operate under its own brand.
Quest completed the acquisition of select clinical testing assets from Fresenius Medical Care's Spectra Laboratories and began providing comprehensive dialysis-related laboratory services for Fresenius-operated centers serving approximately 200,000 patients annually in the United States.
Quest reported record 2025 results with $11.035 billion in revenue (up 11.8%), operating income of $1.556 billion (up 15.6%), and cash from operations of $1.886 billion (up 41.4%). The company raised 2026 guidance and increased its quarterly dividend 7.5% to $0.86 per share.
Quest acquired SBCL to become the clear industry leader in diagnostic testing. SBCL added a national network of regional laboratories, specialty testing operations, STAT laboratories, patient service centers, and a medical sample transport airline. The acquisition doubled Quest's size.
Quest acquired Unilab to significantly expand its West Coast presence, particularly in California. Unilab was a major regional laboratory operator with strong market positions on the West Coast.
Quest acquired AmeriPath to add anatomic pathology and cancer diagnostic testing capabilities. AmeriPath was a leading provider of anatomic pathology, dermatopathology, and molecular diagnostics.
Quest acquired Solstas to expand its geographic footprint in the Southeastern United States and add hospital outreach laboratory relationships in that region.
Quest acquired Blueprint Genetics (Helsinki, Finland) to add genetic testing capabilities for rare diseases and hereditary conditions, expanding Quest's genomics and precision medicine portfolio.
Quest acquired Haystack Oncology, a minimal residual disease (MRD) testing company, to enter the emerging MRD testing market for solid tumors. MRD testing monitors cancer recurrence by detecting circulating tumor DNA.
Quest acquired LifeLabs from OMERS to establish a dominant position in Canadian laboratory services and expand internationally. LifeLabs is Canada's leading lab provider with 6,500+ employees and 8+ million online portal users.
Quest acquired select clinical testing assets from Fresenius Medical Care's Spectra Laboratories to expand renal-specific testing capabilities for dialysis patients.